Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.

Authors

null

Ali Jalali

The University of Texas MD Anderson Cancer Center, Houston, TX

Ali Jalali , Jing Wang , Won-Chul Lee , Jianhua Zhang , Chia Chin Wu , Don Lynn Gibbons , XiMing Tang , Neda Kalhor , Julie Izzo , Carmen Behrens , Frank V. Fossella , Anne S. Tsao , J. Jack Lee , Stephen Swisher , John Heymach , Andrew Futreal , Ignacio Ivan Wistuba , Roy S. Herbst , Vassiliki Papadimitrakopoulou , Jianjun Zhang

Organizations

The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, Yale School of Medicine, New Haven, CT

Research Funding

NIH

Background: In many types of cancer, infiltration of tumor by immune cells, as a reflection of the immune response against the tumor, is thought to play a critical role in clinical outcome. Tumors, however, tend to evade the immune response as they progress. In this study, we characterize the interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer (NSCLC). Methods: We performed histologic immune profiling and microarray expression analysis on primary tumor specimens from 275 NSCLC patients (PR: PROSPECT trial) as well as RNA-Seq expression analysis on biopsy specimens from 50 patients with advanced NSCLC (B2: BATTLE-2 trial). RNA-Seq data from the TCGA lung cancer project was also analyzed. Immune Infiltration Score (IIS) was computed from the expression data using the Estimate package in R. Immune Suppression Score (ISS) was defined as the difference between the mean of CD3, CD4, CD8, FOXP3, and PD1 counts in the periphery and core of the tumor. Results: Tumor IIS is correlated (all p < 0.0005) with tumor immune infiltration as measured by inflammatory cell count on frozen tumor or several immune marker counts in tumor core. IIS is positively associated with survival (p = 0.04) independently of age (p = 0.008) and stage (p = 8e-10). IIS in the top half is associated with higher median survival vs. bottom half (10.2 vs 2.2 months, p < 0.0001) in B2. In TCGA lung adenocarcinoma samples, IIS is higher in stage I/II disease vs stage III/IV (p = 0.003). For all immune markers in PR samples, periphery of the tumor on average has higher counts vs tumor core (p < 0.0011), and this difference (suppression score) is higher in stage III/IV samples vs stage I/II for CD3, CD4, and CD8 (all p < 0.04) and for FOXP3 and PD1 (p < 0.1). ISS is negatively associated with survival (p = 0.02) independently of age (p = 0.06) and stage (p < 0.0001). Conclusions: As NSCLC tumors progress, immune infiltration in the periphery of the tumor increases while infiltration in the core decreases, reflecting increasing immune suppression. Tumor immune infiltration and suppression, as measured by IIS and ISS, are significant predictors of survival, independently of age and stage.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 35, 2017 (suppl; abstr 8538)

DOI

10.1200/JCO.2017.35.15_suppl.8538

Abstract #

8538

Poster Bd #

274

Abstract Disclosures

Similar Abstracts

First Author: Chang Gon Kim

Abstract

2020 ASCO Virtual Scientific Program

PD-1 or PD-L1 co-localizes with immune cells for prediction of prognosis in non-small cell lung cancer.

First Author: Chengzhi Zhou

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer.

First Author: Takafumi Okayama

First Author: Shuhang Wang